share_log

Piper Sandler Lowers ShockWave Medical (NASDAQ:SWAV) Price Target to $280.00

Piper Sandler Lowers ShockWave Medical (NASDAQ:SWAV) Price Target to $280.00

吹笛者桑德勒將衝擊波醫療(納斯達克:SWAV)目標價格目標價格降至 280.00 美元
Defense World ·  2023/01/28 02:45

ShockWave Medical (NASDAQ:SWAV – Get Rating) had its price target decreased by Piper Sandler from $300.00 to $280.00 in a research report issued to clients and investors on Thursday, The Fly reports. The firm currently has an "overweight" rating on the stock. Piper Sandler's price objective indicates a potential upside of 49.07% from the company's current price.

據The Fly報道,在週四發佈給客户和投資者的一份研究報告中,派珀·桑德勒將衝擊波醫療(納斯達克:SWAVE-GET評級)的目標價從300.00美元下調至280.00美元。該公司目前對該股的評級為“增持”。派珀·桑德勒的目標價顯示,該公司目前的價格可能上漲49.07%。

SWAV has been the subject of a number of other reports. Wells Fargo & Company lowered shares of ShockWave Medical from an "overweight" rating to an "equal weight" rating and reduced their price target for the stock from $300.00 to $235.00 in a research note on Monday, December 12th. Morgan Stanley reduced their price target on shares of ShockWave Medical from $290.00 to $224.00 and set an "equal weight" rating for the company in a research note on Friday, January 6th. Bank of America lifted their price target on shares of ShockWave Medical from $260.00 to $310.00 in a research note on Monday, November 7th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of ShockWave Medical in a research note on Friday, December 16th. They issued a "buy" rating and a $285.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $244.44.

SWAV一直是其他一些報告的主題。12月12日,富國銀行在一份研究報告中將Shockwave Medical的股票評級從增持下調至同等權重,並將該股的目標價從300.00美元下調至235.00美元。1月6日,摩根士丹利在一份研究報告中將衝擊波醫療的目標股價從290.00美元下調至224.00美元,並對該公司設定了“同等權重”的評級。11月7日,週一,美國銀行在一份研究報告中將Shockwave Medical的目標股價從260.00美元上調至310.00美元。最後,德意志銀行Aktiengesellschaft在12月16日星期五的一份研究報告中開始報道Shockwave Medical的股票。他們對該公司的評級為“買入”,目標價為285.00美元。一名投資分析師對該股的評級為賣出,兩名分析師給出了持有評級,六名分析師對該公司發出了買入評級。根據MarketBeat.com的數據,該股目前的平均評級為“中等買入”,共識目標價為244.44美元。

Get
到達
ShockWave Medical
衝擊波醫療
alerts:
警報:

ShockWave Medical Stock Down 3.5 %

衝擊波醫療類股下跌3.5%

NASDAQ:SWAV opened at $187.83 on Thursday. The firm has a market cap of $6.79 billion, a P/E ratio of 80.61 and a beta of 1.04. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.02 and a current ratio of 7.29. ShockWave Medical has a fifty-two week low of $113.36 and a fifty-two week high of $320.54. The firm has a 50-day simple moving average of $215.90 and a two-hundred day simple moving average of $247.60.

納斯達克:SWAV週四開盤報187.83美元。該公司市值為67.9億美元,市盈率為80.61倍,貝塔係數為1.04。該公司的負債權益比率為0.04,速動比率為6.02,流動比率為7.29。Shockwave Medical的52周低點為113.36美元,52周高點為320.54美元。該公司的50日簡單移動均線切入位在215.90美元,200日簡單移動均線切入位在247.60美元。

ShockWave Medical (NASDAQ:SWAV – Get Rating) last released its quarterly earnings data on Monday, November 7th. The company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.68 by $0.24. The business had revenue of $131.33 million during the quarter, compared to analyst estimates of $125.85 million. ShockWave Medical had a net margin of 20.48% and a return on equity of 30.08%. Analysts predict that ShockWave Medical will post 2.94 earnings per share for the current fiscal year.
衝擊波醫療(納斯達克:SWAV-GET評級)最近一次發佈季度收益數據是在11月7日(星期一)。該公司公佈本季度每股收益為0.92美元,比分析師普遍預期的0.68美元高出0.24美元。該業務本季度營收為1.3133億美元,而分析師預期為1.2585億美元。Shockwave Medical的淨利潤率為20.48%,股本回報率為30.08%。分析師預測,衝擊波醫療公司本財年的每股收益將達到2.94美元。

Insider Buying and Selling

內幕買賣

In related news, insider Isaac Zacharias sold 4,000 shares of the firm's stock in a transaction that occurred on Friday, November 25th. The shares were sold at an average price of $261.82, for a total value of $1,047,280.00. Following the transaction, the insider now owns 73,021 shares of the company's stock, valued at $19,118,358.22. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other ShockWave Medical news, Director Frank T. Watkins sold 3,000 shares of ShockWave Medical stock in a transaction that occurred on Thursday, November 17th. The shares were sold at an average price of $244.44, for a total transaction of $733,320.00. Following the transaction, the director now owns 3,796 shares of the company's stock, valued at $927,894.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Isaac Zacharias sold 4,000 shares of ShockWave Medical stock in a transaction that occurred on Friday, November 25th. The shares were sold at an average price of $261.82, for a total transaction of $1,047,280.00. Following the transaction, the insider now directly owns 73,021 shares in the company, valued at approximately $19,118,358.22. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 61,300 shares of company stock valued at $13,881,584. 3.90% of the stock is owned by insiders.

在相關新聞中,內部人士Isaac Zacharias在11月25日星期五的一筆交易中出售了4000股該公司的股票。這些股票的平均價格為261.82美元,總價值為1,047,280.00美元。交易完成後,這位內部人士現在持有該公司73,021股股票,價值19,118,358.22美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可通過這個環節。在其他衝擊波醫療新聞方面,董事弗蘭克·T·沃特金斯在11月17日(星期四)的一筆交易中出售了3,000股衝擊波醫療股票。這些股票以244.44美元的平均價格出售,總成交額為733,320.00美元。交易完成後,董事現在持有該公司3796股股票,價值927,894.24美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可通過美國證券交易委員會網站。此外,內部人士艾薩克·扎卡里亞斯在11月25日星期五的一筆交易中出售了4,000股Shockwave Medical股票。這些股票的平均價格為261.82美元,總成交金額為1,047,280.00美元。交易完成後,這位內部人士現在直接擁有該公司73,021股,價值約19,118,358.22美元。關於這次銷售的披露可以找到這裏。在上個季度,內部人士出售了61,300股公司股票,價值13,881,584美元。3.90%的股份由內部人士持有。

Hedge Funds Weigh In On ShockWave Medical

對衝基金參與ShockWave Medical

Several large investors have recently added to or reduced their stakes in SWAV. Fifth Third Bancorp raised its position in shares of ShockWave Medical by 1.8% during the third quarter. Fifth Third Bancorp now owns 2,121 shares of the company's stock valued at $590,000 after buying an additional 37 shares during the last quarter. Profund Advisors LLC raised its position in shares of ShockWave Medical by 1.9% during the third quarter. Profund Advisors LLC now owns 2,386 shares of the company's stock valued at $663,000 after buying an additional 45 shares during the last quarter. Signaturefd LLC raised its position in shares of ShockWave Medical by 14.2% during the third quarter. Signaturefd LLC now owns 362 shares of the company's stock valued at $101,000 after buying an additional 45 shares during the last quarter. Fulton Bank N.A. raised its position in shares of ShockWave Medical by 5.7% during the fourth quarter. Fulton Bank N.A. now owns 1,020 shares of the company's stock valued at $209,000 after buying an additional 55 shares during the last quarter. Finally, Parallel Advisors LLC raised its position in shares of ShockWave Medical by 6.6% during the second quarter. Parallel Advisors LLC now owns 938 shares of the company's stock valued at $179,000 after buying an additional 58 shares during the last quarter. Hedge funds and other institutional investors own 90.56% of the company's stock.

幾家大型投資者最近增持或減持了SWAV的股份。Five Third Bancorp在第三季度將其在Shockwave Medical的股票頭寸提高了1.8%。Five Third Bancorp在上個季度又購買了37股,現在擁有2121股該公司股票,價值59萬美元。Profund Advisors LLC在第三季度將其在Shockwave Medical的股票頭寸提高了1.9%。Profund Advisors LLC現在擁有2386股該公司股票,價值66.3萬美元,在上個季度又購買了45股。Signaturefd LLC在第三季度將其在Shockwave Medical的股票頭寸增加了14.2%。Signaturefd LLC在上個季度又購買了45股,現在擁有362股該公司股票,價值10.1萬美元。富爾頓銀行(Fulton Bank N.A.)在第四季度將Shockwave Medical的股票頭寸提高了5.7%。富爾頓銀行(Fulton Bank N.A.)在上個季度又購買了55股,現在持有1,020股該公司股票,價值20.9萬美元。最後,Parly Advisors LLC在第二季度將其在Shockwave Medical的股票頭寸提高了6.6%。Parly Advisors LLC現在擁有該公司938股股票,價值17.9萬美元,在上個季度又購買了58股。對衝基金和其他機構投資者持有該公司90.56%的股票。

About ShockWave Medical

關於衝擊波醫療

(Get Rating)

(獲取評級)

Shockwave Medical, Inc operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease, C2 catheters for treating coronary artery disease, and S4 catheters or treating below-the-knee peripheral artery disease.

ShockWave Medical,Inc.是一家醫療設備公司,專注於開發旨在改變鈣化心血管疾病治療方式的產品並將其商業化。該公司提供用於治療膝蓋以上週圍動脈疾病的M5導管,用於治療冠狀動脈疾病的C2導管,以及用於治療膝蓋以下週圍動脈疾病的S4導管。

Featured Articles

專題文章

  • Get a free copy of the StockNews.com research report on ShockWave Medical (SWAV)
  • MarketBeat Week in Review – 1/23- 1/27
  • Why Lucid Spiked Nearly 100% In One Day
  • Ride These Railroad Stocks for Growth and Income
  • ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
  • KLA Corporation: Strength In A Troubled Semi-Market
  • 免費獲取StockNews.com關於Shockwave Medical(SWAV)的研究報告
  • 市場回顧周-1/23-1/27
  • 為什麼Lucid在一天內飆升了近100%
  • 利用這些鐵路股票實現增長和收入
  • ASML預計今年芯片需求回升,提振銷售觀點
  • KLA公司:在動盪不安的半市場中站穩腳跟

Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.

接受《衝擊波醫學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對ShockWave Medical和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論